Claremont Financial Group’s Bristol-Myers Squibb BMY Stock Holding History

Claremont Financial Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$116K	Buy	+1,500	New	+$101K	0.5%	15

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Claremont Financial Group's BMY Position: Q1 2022 in Review

Claremont Financial Group opened a new position in Bristol-Myers Squibb (BMY) in Q1 2022: 1,500 shares worth $116K. The stake represents 0.5% of the portfolio and ranks #15 among its holdings.

2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

Claremont Financial Group held 1,500 shares of Bristol-Myers Squibb worth $116K as of Q1 2022.
Bristol-Myers Squibb was a new Claremont Financial Group position in Q1 2022.
Bristol-Myers Squibb made up 0.5% of Claremont Financial Group's portfolio in Q1 2022, its #15 holding.
2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on Claremont Financial Group's 13F filing for Q1 2022, filed 15 Apr 2022.